Consensus Tempus AI, Inc.

Stocks

TEM

US88023B1035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:28:30 31/10/26 am AEDT			5-day change	1st Jan Change
73.09 ^USD	-6.10%		+8.06%	+23.74%

27/10	Tempus AI Receives EU Certification for xR RNA Sequencing	MT
24/10	Tempus AI, Inc. Enters Into Multi-Year Agreement With Bristol Myers Squibb To License Multimodal Oncology Data	CI

Evolution of the Average Target: Tempus AI, Inc.

Evolution of the Target Price: Tempus AI, Inc.

Changes in Analyst Recommendations: Tempus AI, Inc.

7e4e6868da2456a954a30dcd5b01.W3Gi4BbDD674opd_NHahJv8hZnAn-m7VRJ2oirxYfnY.CQCXmHf0Vee66u1JVg_gcqxoUghglzqjI6nmuv0LR0RqGJezVKtZyr2Q0g~64e71b1daa3fc68bce0d669f5b0d39d3

Analysts' recommendations: Tempus AI, Inc.

21/09	Goldman Sachs Initiates Tempus AI at Neutral With $75 Price Target	MT
09/09	UBS Initiates Coverage on Tempus AI With Neutral Rating, $70 Price Target	MT
08/09	Rothschild & Co Redburn Initiates Tempus AI at Neutral With $67 Price Target	MT
02/09	Cantor Fitzgerald Initiates Tempus AI at Overweight With $80 Price Target	MT
01/09	Piper Sandler Upgrades Tempus AI to Overweight From Neutral, Adjusts PT to $76 From $56	MT
01/09	Analyst recommendations: Duolingo, Robinhood, Adobe, CrowdStrike, Salesforce…
21/07	Personalis Acquisition Price Warranted by Growth Prospects, Needham Says	MT
21/07	Tempus AI to Buy Cancer Test Maker Personalis; Needham Says Deal Premium Well Above Peers	MT
21/07	Top Midday Decliners	MT
13/04	TD Cowen Upgrades Tempus AI to Buy From Hold, Adjusts Price Target to $65 From $70	MT
13/04	Jefferies Initiates Tempus AI at Underperform With $35 Price Target	MT
25/02	Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead…
19/02	Mizuho Securities Initiates Coverage on Tempus AI With Outperform Rating, $100 Price Target	MT
17/02	Baird Initiates Tempus AI at Outperform With $59 Price Target	MT
02/12	Morgan Stanley Raises Price Target on Tempus AI to $85 From $80, Keeps Overweight Rating	MT
11/11	Analyst recommendations: Coreweave, Duolingo, Lyft, Qualcomm, Tempus…
22/10/25	Analyst recommendations: 3M Company, Gartner, Halliburton, GM, Warner Bros Discovery…
22/10/25	Tempus AI Shares Lower After TD Cowen Downgrade	MT
21/10/25	TD Cowen Downgrades Tempus AI to Hold From Buy, Adjusts Price Target to $88 From $72	MT
20/10/25	Canaccord Genuity Initiates Coverage on Tempus AI With Buy Rating, $110 Price Target	MT
02/09/25	HC Wainwright Initiates Tempus AI at Buy With $90 Price Target	MT
06/08/25	Healthcare firm Personalis' Q2 revenue misses estimates	RE
21/04/25	BTIG Initiates Tempus AI at Buy With $60 Price Target	MT
27/02/25	Wolfe Research Downgrades Tempus AI to Peer Perform From Outperform	MT
26/02/25	Tempus AI Shares Fall After Downgrade from JPMorgan	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TEMPUS AI, INC.					-3.58%
	WUXI APPTEC CO., LTD.					+41.6%
	ARGENX SE					+24.9%
	LONZA GROUP AG					+8.71%
	IQVIA HOLDINGS INC.					+12.62%
	BEONE MEDICINES AG					+17.47%
	REVOLUTION MEDICINES, INC.					+36.04%
	GENMAB A/S					+1%
	CELLTRION, INC.					+42.98%
	WUXI BIOLOGICS (CAYMAN) INC.					+33.85%
	Average					+21.56%
	Weighted average by Cap.					+23.35%